# OnCo record advanced-stage-classical-hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "advanced-stage-classical-hodgkin-lymphoma" ;
  schema:name "Advanced-stage classical Hodgkin lymphoma (stage III to IV)"@en ;
  schema:alternateName "Stage III to IV classical Hodgkin lymphoma"@en, "Advanced Hodgkin lymphoma"@en, "Disseminated Hodgkin lymphoma"@en, "High-risk Hodgkin lymphoma (IPS 4 or more)"@en ;
  schema:description "Advanced-stage classical Hodgkin lymphoma is Hodgkin lymphoma involving nodes on both sides of the diaphragm or organs such as the liver, lungs or bone marrow. It is treated with six cycles of combination chemotherapy, and two trials changed the standard: replacing bleomycin with brentuximab vedotin (ECHELON-1) and then with nivolumab (SWOG S1826), which cured more patients with less toxicity."@en ;
  schema:url <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2405888>, <https://doi.org/10.1056/NEJMoa1708984>, <https://doi.org/10.1016/S0140-6736(24)01315-1>, <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  onco:tag "subtype-page", "haematologic" ;
  onco:related <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:targets <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/reed-sternberg-cell/>, <https://onco.cc/terms/late-effects/> ;
  onco:trials <https://onco.cc/trials/echelon-1/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/trials/nct02979522/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/>, <https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/>, <https://onco.cc/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/>, <https://onco.cc/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/> ;
  onco:pipeline <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/nct02979522/>, <https://onco.cc/pairings/pd1-plus-avd-hodgkin/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/ideas/idea-chemo-free-hodgkin/> ;
  onco:standardOfCare <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/trials/echelon-1/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/pairings/pd1-plus-avd-hodgkin/>, <https://onco.cc/pairings/bleomycin-omission-caution/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/trials/nct02979522/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/late-effects/> .